Table 1.
Clinical parameters at baseline
| Healthy controls (n = 15) | Pulmonary hypertension (n = 30) | p value | |
|---|---|---|---|
| Age (years) | 39 ± 15 | 54 ± 12 | 0.0011 |
| Male | 10 (66.6%) | 9 (30%) | 0.0189 |
| Weight (kg) | 72 ± 16 | 70 ± 12 | 0.6772 |
| Height (cm) | 172 ± 10 | 164 ± 8 | 0.0063 |
| Body surface area (m2) | 1.85 ± 0.25 | 1.79 ± 0.17 | 0.3154 |
| PH | |||
| Group I, PAH (n) | 23 | ||
| Group IV, CTEPH (n) | 7 | ||
| WHO functional class (II/III) | 26/4 | ||
| 6 MWD (m) | 473 ± 75 | ||
| *FEV1 (L) | 3.56 (3.36, 4.26) | 2.15 (1.85, 2.78) | <0.0001 |
| *FVC (L) | 4.40 (4.04, 4.95) | 2.99 (2.47, 3.85) | <0.0001 |
| Echocardiography | |||
| PA systolic (mmHg) | 25 ± 4 | 71 ± 24 | <0.0001 |
| TAPSE (mm) | 26.0 ± 3.6 | 20.4 ± 3.8 | <0.0001 |
| RVMPI | 0.21 ± 0.09 | 0.57 ± 0.30 | <0.0001 |
| Hemodynamic | |||
| Mean PA pressure (mmHg) | 46 ± 12 | ||
| PVR (Wood units) | 7.2 ± 4.0 | ||
| Right atrial pressure (mmHg) | 7.8 ± 4.4 | ||
| Cardiac output (L/min) | 5.1 ± 1.2 | ||
| *eGFR (ml/min/1.73 m2) | 96 (90, 111) | 80 (73, 89) | 0.0008 |
| *NT-proBNP (ng/L) | 29 (11, 56) | 141 (78, 532) | <0.0001 |
Values are mean ± sd , median (Q1, Q3) or n (%)
PH pulmonary hypertension; PAH pulmonary arterial hypertension; CTEPH chronic thromboembolic pulmonary hypertension; WHO World Health Organization; 6 MWD 6-min walking distance; FEV 1 forced expiratory volume in 1 s; FVC forced vital capacity; PA pulmonary artery; TAPSE tricuspid annulus plane systolic excursion; RVMPI right ventricular myocardial performance index; PVR pulmonary vascular resistance; eGFR estimated glomerulare filtration rate; NT-proBNP N-terminal pro-brain natriuretic peptide.
* p-value based on log-transformed data